Voyager Therapeutics (VYGR) Now Covered by Analysts at BTIG Research
Other analysts have also recently issued research reports about the company. Cowen reissued a buy rating on shares of Voyager Therapeutics in a research report on Tuesday, October 31st. Canaccord Genuity began coverage on Voyager Therapeutics in a research report on Friday, October 27th. They set a buy rating and a $35.00 price objective for the company. Stifel Nicolaus reissued a buy rating and set a $31.00 price objective (up previously from $20.00) on shares of Voyager Therapeutics in a research report on Monday, October 23rd. Chardan Capital reissued a hold rating and set a $17.00 price objective on shares of Voyager Therapeutics in a research report on Tuesday, October 31st. Finally, ValuEngine raised Voyager Therapeutics from a sell rating to a hold rating in a research report on Saturday, September 30th. Three investment analysts have rated the stock with a sell rating, one has given a hold rating and eleven have assigned a buy rating to the stock. The stock presently has a consensus rating of Buy and a consensus target price of $26.33.
Shares of Voyager Therapeutics (NASDAQ VYGR) traded up $0.13 during trading on Tuesday, hitting $14.16. The stock had a trading volume of 349,000 shares, compared to its average volume of 256,070. Voyager Therapeutics has a 1-year low of $8.10 and a 1-year high of $25.99.
Several institutional investors have recently bought and sold shares of the company. Iguana Healthcare Management LLC bought a new position in Voyager Therapeutics during the third quarter valued at about $515,000. Point72 Asset Management L.P. bought a new position in Voyager Therapeutics during the third quarter valued at about $2,695,000. Dimensional Fund Advisors LP grew its stake in shares of Voyager Therapeutics by 7.9% in the 3rd quarter. Dimensional Fund Advisors LP now owns 105,914 shares of the company’s stock valued at $2,181,000 after purchasing an additional 7,786 shares during the period. Schwab Charles Investment Management Inc. grew its stake in shares of Voyager Therapeutics by 71.5% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 49,788 shares of the company’s stock valued at $1,026,000 after purchasing an additional 20,753 shares during the period. Finally, Mckinley Capital Management LLC Delaware bought a new stake in shares of Voyager Therapeutics in the 3rd quarter valued at approximately $1,412,000. Institutional investors and hedge funds own 35.97% of the company’s stock.
TRADEMARK VIOLATION WARNING: This article was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another website, it was stolen and republished in violation of United States & international copyright law. The legal version of this article can be read at https://www.thecerbatgem.com/2017/12/20/voyager-therapeutics-vygr-now-covered-by-analysts-at-btig-research.html.
About Voyager Therapeutics
Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.